ARTICLE | Clinical News
LJPC to begin Phase I/II
September 11, 2001 7:00 AM UTC
La Jolla Pharmaceutical (LJPC) filed an IND with the FDA to start Phase I/II trials of LJP 1082 to treat antibody mediated thrombosis. LJP 1082 is a toleragen that binds to antibodies against beta 2 g...